Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Alcohol use disorder (AUD) is notoriously difficult to treat, but a new therapeutic option may be on the horizon. Ondansetron, a competitive serotonin type 3 receptor antagonist currently…
Neuroplasticity, or the brain’s ability to rewire and “heal” itself, is of particular interest in modern post-stroke care. However, data show that only 8-10 percent of stroke victims…
Specially trained dogs detected malaria by smelling the socks of sick patients—something researchers hope could eventually help control the spread of the disease.
Alcohol is the world’s seventh-leading cause of disease burden, researchers found, and is the top risk factor for a variety of diseases in people ages 15-49. Over time,…
A new electronic implant can dissolve harmlessly in the body after working to repair damaged nerves. Working in the fledgling field of bioelectronic medicine, researchers at Northwestern University…
Genome surgery uses the powerful, and still controversial, CRISPR/Cas9 gene-editing tool to remove specific genes from a person’s DNA. UCSF researchers, in collaboration with UC Berkeley and the…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
A research team from Brazil evaluated the link between anxiety and depression — nonmotor symptoms of Parkinson’s disease (PD) — and freezing of gait. They found that roughly…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
